GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Receptos Inc (FRA:13R) » Definitions » Securities & Investments

Receptos (FRA:13R) Securities & Investments


View and export this data going back to . Start your Free Trial

What is Receptos Securities & Investments?

Securities & Investments only applies to banks.


Receptos Business Description

Traded in Other Exchanges
N/A
Address
Receptos Inc was incorporated in the state of Delaware on September 26, 2008 under the name Receptor Pharmaceuticals, Inc. and changed its name to name to Receptos, Inc. on May 11, 2009. The Company is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune disorders. Its product candidates span three distinct specialty disease areas. The first asset, RPC1063, is developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), which is an Orphan Disease. The Company contract with third parties for the manufacture of RPC1063 for preclinical studies. The Company's competitors includes major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. In addition to regulations in the US, the company is subject to regulations of other countries governing clinical trials and commercial sales and distribution of its products.